Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Multidrug Resistant Bacteria Market?

The market for multidrug resistant bacteria has witnessed substantial growth in the past few years. It is projected to expand from $12.61 billion in 2024 to $13.27 billion in 2025, marking a compound annual growth rate (CAGR) of 5.2%. Factors contributing to the growth during the historic period include the crisis of antibiotic resistance, advancements in drug discovery, regulatory incentives, and public health initiatives.

In the upcoming years, the market size for multidrug resistant bacteria is predicted to witness robust growth. With a compound annual growth rate (CAGR) of 6.8%, its size is estimated to reach “$17.28 billion by 2029. The projected growth during this period is linked to factors such as antibiotic stewardship programs, worldwide spread of resistance, phage therapy and alternative treatments, as well as both public and private investments. Key trends expected during this forecast period comprise precision medicine for infectious diseases, combination therapies, continual surveillance and monitoring, and global collaboration.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13044&type=smp

Which Factors Are Steering Growth In The Multidrug Resistant Bacteria Market?

The growth of the multidrug-resistant bacteria market is predicted to be driven by the rising occurrence of infectious diseases. These diseases are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites. Multidrug-resistant bacteria are of particular concern in infectious diseases due to their potential to cause infections that conventional antibiotics struggle to treat. These types of bacteria have evolved to become resistant to several antibiotics, therefore reducing the effectiveness of commonly used medications to fight bacterial infections. For instance, an article released by the US-based national public health agency, Centers for Disease Control and Prevention, in November 2023 reported that the count of tuberculosis patients in the US has risen from 8,320 in 2022 to 9,615 in 2023, marking an increase of 1,295 cases. Consequently, the rise in infectious diseases will stimulate the market for multidrug-resistant bacteria.

Which Segmentation Factors Are Critical In The Multidrug Resistant Bacteria Market Analysis?

The multidrug resistant bacteria market covered in this report is segmented –

1) By Disease: Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, Acute Bacterial Skin And Skin Structure Infections, Hospital Acquired Bacterial Pneumonia, Acquired Bacterial Pneumonia, Other Diseases

2) By Drug Class: Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies, Other Drug Classes

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Urinary Tract Infection: Cystitis, Pyelonephritis

2) By Intra-Abdominal Infections: Appendicitis, Peritonitis

3) By Blood Stream Infections: Bacteremia, Sepsis

4) By Clostridium Difficile Infections: Mild CDI, Severe CDI

5) By Acute Bacterial Skin And Skin Structure Infections: Cellulitis, Abscesses

6) By Hospital Acquired Bacterial Pneumonia: Ventilator-Associated Pneumonia, Hospital-Acquired Pneumonia

7) By Acquired Bacterial Pneumonia: Community-Acquired Pneumonia, Aspiration Pneumonia

By Other Diseases: Bone and Joint Infections, Endocarditis

What Are The Dominant Trends Currently Seen In The Multidrug Resistant Bacteria Market?

Primary players in the multidrug-resistant bacteria market are directing their efforts towards the creation of novel drugs and securing approvals to cater to the demands of an emerging consumer segment. To curb the escalation of antibiotic resistance, granting approvals for drugs targeting multidrug-resistant bacteria is essential. For example, in May 2023, Entasis Therapeutics Inc., a biotechnology firm based in the US, obtained clearance from the Food and Drug Administration (FDA) for Xacduor, an antibiotic combination devised to combat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VAP) instigated by acinetobacter baumannii, a stubborn pathogen. This concoction comprises ceftolozane, a cephalosporin antibiotic, and tedizolid phosphate, a newcomer in the oxazolidinone category. Furthermore, it presents a novel alternative for patients infected with Acinetobacter baumannii who have demonstrated no response to previous treatment regimens. This treatment option can be administered via an injection that merges the antibiotic beta-lactam sulbactam and the broad-spectrum beta-lactamase inhibitor durlobactam, decreasing acinetobacter resistance and enhancing the functionality of the antibiotic.

Which Companies Hold A Competitive Edge In The 359 Market?

Major players in the multidrug resistant bacteria market are Pfizer Inc., Johnson And Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals Inc., BioMarin Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Alkem Laboratories, Wockhardt Ltd., Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Theravance Biopharma Inc., Melinta Therapeutics Inc., Armata Pharmaceuticals Inc., Tetraphase Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report

Which Region Is Leading Innovation In The Multidrug Resistant Bacteria Market?

North America was the largest region in the multidrug-resistant bacteria market in 2024. The regions covered in multidrug-resistant bacteria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13044&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model